[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Formoterol.]
[J01EC02, sulfadiazine, The metabolism of Formoterol can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Formoterol can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Formoterol can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Formoterol can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Formoterol can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Formoterol can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Formoterol.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sulpiride.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Formoterol.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Formoterol is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of hypokalemia can be increased when Mercaptopurine is combined with Formoterol.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Formoterol.]
[L01CB02, teniposide, The metabolism of Formoterol can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Terbutaline may increase the sympathomimetic activities of Formoterol.]
[G03BA03, testosterone, The metabolism of Formoterol can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Formoterol can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Formoterol.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be decreased when combined with Formoterol.]
[R03DA07, theobromine, The risk or severity of hypokalemia can be increased when Theobromine is combined with Formoterol.]
[R03DA04, theophylline, The risk or severity of hypokalemia can be increased when Theophylline is combined with Formoterol.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Formoterol is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Eribulin.]
[N05CA19, thiopental, The metabolism of Formoterol can be decreased when combined with Thiopental.]
[N05AB08, thioproperazine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Formoterol can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Formoterol.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Formoterol is combined with Moxisylyte.]
[B01AC05, ticlopidine, The metabolism of Formoterol can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Timolol may decrease the bronchodilatory activities of Formoterol.]
[A10BB05, tolazamide, The metabolism of Formoterol can be decreased when combined with Tolazamide.]
[M02AX02, tolazoline, The therapeutic efficacy of Formoterol can be decreased when used in combination with Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Formoterol.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Formoterol.]
[N02AX02, tramadol, The metabolism of Formoterol can be decreased when combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Formoterol.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Formoterol.]
[L01XF01, tretinoin, The metabolism of Formoterol can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Formoterol.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Formoterol is combined with Mepenzolate.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Trifluoperazine.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Formoterol.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Formoterol.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Formoterol.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Formoterol.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Formoterol.]
[C02BA01, trimethaphan, Formoterol may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Formoterol can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Formoterol.]
[R06AC04, tripelennamine, The metabolism of Formoterol can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Formoterol.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Formoterol can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Formoterol may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Formoterol is combined with Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Formoterol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of adverse effects can be increased when Linagliptin is combined with Formoterol.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ezogabine.]
[R03AC18, indacaterol, Indacaterol may increase the sympathomimetic activities of Formoterol.]
[B01AC24, ticagrelor, The metabolism of Formoterol can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The therapeutic efficacy of Formoterol can be decreased when used in combination with Verapamil.]
[N06AX09, viloxazine, The metabolism of Formoterol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Formoterol can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Formoterol may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The metabolism of Formoterol can be increased when combined with Warfarin.]
[N01AX15, xenon, Xenon may increase the arrhythmogenic activities of Formoterol.]
[C03BA10, xipamide, Formoterol may decrease the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Formoterol can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Formoterol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Formoterol.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Formoterol can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Formoterol can be decreased when combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Formoterol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Formoterol.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Formoterol.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Tolterodine.]
[C07AB03, atenolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Formoterol.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Formoterol.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Formoterol.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Formoterol.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Formoterol.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Formoterol.]
[A08AA11, lorcaserin, The metabolism of Formoterol can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Formoterol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Formoterol can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, The serum concentration of Formoterol can be decreased when it is combined with Enzalutamide.]
[C01CA18, octopamine, Octopamine may increase the sympathomimetic activities of Formoterol.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Formoterol.]
[L01EX05, regorafenib, The metabolism of Formoterol can be decreased when combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Barbital can be decreased when combined with Formoterol.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Formoterol.]
[S01GA07, brimonidine, Brimonidine may increase the sympathomimetic activities of Formoterol.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Formoterol.]
[C08CA13, lercanidipine, Formoterol may decrease the antihypertensive activities of Lercanidipine.]
[N06DA02, donepezil, The metabolism of Formoterol can be decreased when combined with Donepezil.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Formoterol.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Formoterol can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the arrhythmogenic activities of Formoterol.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Formoterol.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Formoterol can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Formoterol.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Formoterol.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Formoterol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Formoterol can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Bendroflumethiazide.]
[G03XC05, ospemifene, The metabolism of Formoterol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Formoterol is combined with Benorilate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Formoterol can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Formoterol can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Formoterol.]
[M01AH01, celecoxib, The metabolism of Formoterol can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Naratriptan is combined with Formoterol.]
[L04AA18, everolimus, The metabolism of Formoterol can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Formoterol.]
[L01EC02, dabrafenib, The serum concentration of Formoterol can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Formoterol is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Formoterol.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the tachycardic activities of Formoterol.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Bepridil.]
[C02KX05, riociguat, Formoterol may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Formoterol may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Formoterol.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Formoterol.]
[N03AF04, eslicarbazepine, The metabolism of Formoterol can be decreased when combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Formoterol can be increased when it is combined with Luliconazole.]
[S01EA03, apraclonidine, Apraclonidine may increase the sympathomimetic activities of Formoterol.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Formoterol.]
[C01CA27, droxidopa, Droxidopa may increase the sympathomimetic activities of Formoterol.]
[C07AB04, acebutolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Formoterol can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Formoterol can be increased when combined with Apremilast.]
[N07CA01, betahistine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Betahistine.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Formoterol.]
[S01ED02, betaxolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Betaxolol.]
[V03AB34, fomepizole, The metabolism of Formoterol can be decreased when combined with Fomepizole.]
[C02CC01, bethanidine, Bethanidine may increase the sympathomimetic activities of Formoterol.]
[L04AC11, siltuximab, The metabolism of Formoterol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Formoterol can be decreased when combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Formoterol.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Formoterol.]
[R03AC19, olodaterol, Olodaterol may increase the sympathomimetic activities of Formoterol.]
[A16AX10, eliglustat, The metabolism of Formoterol can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Formoterol can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Acepromazine.]
[V04CX03, methacholine, Formoterol may decrease effectiveness of Methacholine as a diagnostic agent.]
[N04AA02, biperiden, The metabolism of Formoterol can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Formoterol.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Formoterol.]
[B01AA01, dicumarol, The metabolism of Formoterol can be decreased when combined with Dicoumarol.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Formoterol.]
[L04AC10, secukinumab, The metabolism of Formoterol can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Formoterol.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Formoterol can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Formoterol can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Formoterol can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Formoterol can be decreased when used in combination with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Formoterol can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Formoterol is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Formoterol is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Formoterol is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Formoterol is combined with Acemetacin.]
[A02BC03, lansoprazole, The metabolism of Formoterol can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Formoterol.]
[J02AC05, isavuconazole, The metabolism of Formoterol can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Formoterol may decrease the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, The metabolism of Formoterol can be decreased when combined with Acetohexamide.]
[G04CA01, alfuzosin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Alfuzosin.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Formoterol.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Formoterol is combined with Alminoprofen.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Formoterol.]
[N04BC01, bromocriptine, Bromocriptine may increase the sympathomimetic activities of Formoterol.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Formoterol.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Amineptine is combined with Formoterol.]
[C08CA01, amlodipine, Formoterol may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Bumetanide.]
[N01BB01, bupivacaine, The metabolism of Formoterol can be decreased when combined with Bupivacaine.]
[C07AA19, bupranolol, Bupranolol may decrease the bronchodilatory activities of Formoterol.]
[N07BC01, buprenorphine, The metabolism of Formoterol can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Formoterol.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Formoterol can be decreased when combined with Rabeprazole.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Formoterol.]
[S01GX07, azelastine, The metabolism of Formoterol can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Formoterol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Formoterol is combined with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may increase the sympathomimetic activities of Formoterol.]
[R03DA08, bamifylline, The risk or severity of hypokalemia can be increased when Bamifylline is combined with Formoterol.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Formoterol.]
[N06BC01, caffeine, The risk or severity of hypokalemia can be increased when Caffeine is combined with Formoterol.]
[C09AA07, benazepril, Formoterol may decrease the antihypertensive activities of Benazepril.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Formoterol.]
[J05AE09, tipranavir, The metabolism of Formoterol can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Formoterol.]
[L04AB02, infliximab, The metabolism of Formoterol can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Formoterol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Delafloxacin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Formoterol is combined with Acetylcholine.]
[L01BC06, capecitabine, The metabolism of Formoterol can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Formoterol.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may increase the sympathomimetic activities of Formoterol.]
[J05AG03, efavirenz, The metabolism of Formoterol can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may decrease the bronchodilatory activities of Formoterol.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Bornaprine.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Formoterol is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Formoterol is combined with Bumadizone.]
[J05AX18, letermovir, The metabolism of Formoterol can be increased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Butriptyline is combined with Formoterol.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Acetyldigoxin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Acrivastine.]
[C09AA01, captopril, Formoterol may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Formoterol can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Formoterol can be decreased when combined with Carbamazepine.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Formoterol can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Formoterol can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Encorafenib.]
[C07AB08, celiprolol, Celiprolol may increase the sympathomimetic activities of Formoterol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Formoterol.]
[L01XX62, ivosidenib, The metabolism of Formoterol can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Formoterol.]
[N03AX17, stiripentol, The metabolism of Formoterol can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Formoterol can be decreased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Formoterol.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Formoterol.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Formoterol.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Formoterol is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of hypokalemia can be increased when Oxtriphylline is combined with Formoterol.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Inotersen.]
[M03BA02, carisoprodol, The metabolism of Formoterol can be decreased when combined with Carisoprodol.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Formoterol.]
[L04AA39, emapalumab, The metabolism of Formoterol can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Formoterol.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Cibenzoline.]
[C09AA08, cilazapril, Formoterol may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Formoterol is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Formoterol can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Formoterol.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Formoterol is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Formoterol.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Formoterol.]
[N05BA09, clobazam, The metabolism of Formoterol can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Formoterol.]
[C09CA06, candesartan, Formoterol may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Formoterol can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Formoterol.]
[L01EM03, alpelisib, The serum concentration of Formoterol can be decreased when it is combined with Alpelisib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Cicletanine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Formoterol.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Entrectinib.]
[N07XX11, pitolisant, Formoterol may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Formoterol.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Formoterol.]
[C03AA09, cyclothiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Formoterol is combined with Yohimbine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Formoterol.]
[G03AC09, desogestrel, The metabolism of Formoterol can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Formoterol.]
[N03AX25, cenobamate, The serum concentration of Formoterol can be increased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Formoterol can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Formoterol.]
[R06AB02, dexchlorpheniramine, The metabolism of Formoterol can be decreased when combined with Dexchlorpheniramine.]
[L01EX18, avapritinib, The metabolism of Formoterol can be decreased when combined with Avapritinib.]
[M01AX21, diacetylrhein, The metabolism of Formoterol can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Formoterol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Formoterol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Formoterol is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Formoterol is combined with Dutasteride.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Formoterol.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Formoterol.]
[N02CC06, eletriptan, The metabolism of Formoterol can be increased when combined with Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Formoterol.]
[L01XF03, bexarotene, The metabolism of Formoterol can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Formoterol can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Formoterol can be decreased when combined with Dronedarone.]
[S01EA02, dipivefrin, Dipivefrin may increase the sympathomimetic activities of Formoterol.]
[S03AA08, chloramphenicol, The metabolism of Formoterol can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Chlorcyclizine.]
[C02AA06, methoserpidine, Formoterol may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Dihexyverine.]
[C01CA14, dopexamine, Dopexamine may increase the sympathomimetic activities of Formoterol.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Formoterol.]
[G04BD09, trospium, The metabolism of Formoterol can be decreased when combined with Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Formoterol is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Formoterol is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Formoterol is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Formoterol.]
[C08CA17, levamlodipine, Formoterol may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Formoterol.]
[L04AC19, satralizumab, The serum concentration of Formoterol can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Formoterol.]
[P01BA01, chloroquine, The metabolism of Formoterol can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Formoterol can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Formoterol can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Formoterol can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Formoterol can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Formoterol may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Formoterol can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Formoterol can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Formoterol is combined with Ethenzamide.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Formoterol is combined with Choline salicylate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Formoterol.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Formoterol is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Formoterol can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Formoterol can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Relugolix.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Formoterol is combined with Naxitamab.]
[L01EX21, tepotinib, The metabolism of Formoterol can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Formoterol can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Formoterol is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of hypokalemia can be increased when Fenethylline is combined with Formoterol.]
[C01CA19, fenoldopam, Formoterol may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Formoterol is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Formoterol is combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Formoterol.]
[S01AA13, fusidic acid, The metabolism of Formoterol can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the arrhythmogenic activities of Formoterol.]
[L03AB10, peginterferon alfa-2b, The metabolism of Formoterol can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Formoterol may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Formoterol can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Formoterol can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Formoterol can be decreased when combined with Somapacitan.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Formoterol is combined with Fexinidazole.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Formoterol.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Formoterol can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The metabolism of Formoterol can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Formoterol.]
[R03CC13, clenbuterol, Clenbuterol may increase the sympathomimetic activities of Formoterol.]
[N06AX25, St. John's wort extract, The metabolism of St. John's Wort can be decreased when combined with Formoterol.]
[L01EA06, asciminib, The metabolism of Formoterol can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Formoterol can be decreased when combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Formoterol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Formoterol.]
[C10AB01, clofibrate, The metabolism of Formoterol can be decreased when combined with Clofibrate.]
[L01EJ03, pacritinib, The serum concentration of Formoterol can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Formoterol.]
[S01EA04, clonidine, Clonidine may increase the sympathomimetic activities of Formoterol.]
[C01EB24, mavacamten, The serum concentration of Formoterol can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Formoterol can be decreased when combined with Vonoprazan.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Formoterol can be decreased when combined with Clozapine.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Cocaine.]
[C02KB01, metyrosine, Formoterol may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Formoterol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Formoterol is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Formoterol.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Formoterol is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Formoterol.]
[L04AA13, leflunomide, The metabolism of Formoterol can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, Desflurane may increase the arrhythmogenic activities of Formoterol.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Formoterol is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Formoterol can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Formoterol is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Formoterol is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Formoterol.]
[A03AX10, isometheptene, Isometheptene may increase the sympathomimetic activities of Formoterol.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Almotriptan is combined with Formoterol.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Formoterol is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Formoterol.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Emedastine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Formoterol is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Formoterol can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Formoterol can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Formoterol.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Levocabastine.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Formoterol.]
[N07BC04, lofexidine, Lofexidine may increase the sympathomimetic activities of Formoterol.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Formoterol is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Formoterol is combined with Loxoprofen.]
[C09AA03, lisinopril, Formoterol may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Formoterol can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Formoterol is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may decrease the bronchodilatory activities of Formoterol.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Formoterol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Formoterol.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the sympathomimetic activities of Formoterol.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Cyclizine.]
[C03DA04, eplerenone, Formoterol may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The metabolism of Formoterol can be decreased when combined with Melperone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Formoterol.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Formoterol.]
[S01XA18, cyclosporine, The metabolism of Formoterol can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Formoterol.]
[N06BA07, modafinil, The metabolism of Formoterol can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Formoterol.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Formoterol.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Formoterol.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Formoterol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Formoterol is combined with Morniflumate.]
[C02AC05, moxonidine, Moxonidine may increase the sympathomimetic activities of Formoterol.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Formoterol is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Formoterol.]
[M01AH05, etoricoxib, The metabolism of Formoterol can be decreased when combined with Etoricoxib.]
[J04BA02, dapsone, The metabolism of Formoterol can be decreased when combined with Dapsone.]
[C02CC04, debrisoquin, Formoterol may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The metabolism of Formoterol can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Formoterol.]
[C07AB12, nebivolol, Nebivolol may increase the sympathomimetic activities of Formoterol.]
[N06AX06, nefazodone, Nefazodone may increase the tachycardic activities of Formoterol.]
[C01DX16, nicorandil, Formoterol may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Formoterol can be decreased when combined with Nilutamide.]
[C01CA23, theodrenaline, The risk or severity of hypokalemia can be increased when Theodrenaline is combined with Formoterol.]
[C01CA05, norfenefrine, Norfenefrine may increase the sympathomimetic activities of Formoterol.]
[N06AB10, escitalopram, The serum concentration of Formoterol can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Formoterol is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Formoterol can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Formoterol.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Formoterol.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Formoterol.]
[C09XA02, aliskiren, Formoterol may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Formoterol is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The metabolism of Formoterol can be decreased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Formoterol.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Formoterol is combined with Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Formoterol can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Formoterol can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Formoterol.]
[L04AB04, adalimumab, The metabolism of Formoterol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Formoterol can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Formoterol.]
[R05DA09, dextromethorphan, The metabolism of Formoterol can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Formoterol can be decreased when combined with Paramethadione.]
[N06AB05, paroxetine, The metabolism of Formoterol can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Formoterol can be decreased when combined with Clopidogrel.]
[C04AD01, pentifylline, The risk or severity of hypokalemia can be increased when Pentifylline is combined with Formoterol.]
[N05BA01, diazepam, The metabolism of Formoterol can be decreased when combined with Diazepam.]
[V03AH01, diazoxide, Formoterol may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dibenzepin is combined with Formoterol.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Formoterol.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Formoterol.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Formoterol.]
[C02DG01, pinacidil, Formoterol may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Pinaverium.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Formoterol is combined with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Formoterol.]
[R03CC07, pirbuterol, Pirbuterol may increase the sympathomimetic activities of Formoterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Piretanide.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Diethylpropion is combined with Formoterol.]
[L02AA01, diethylstilbestrol, The metabolism of Formoterol can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Formoterol.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Formoterol.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Poldine.]
[N02BA11, diflunisal, The metabolism of Formoterol can be decreased when combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Formoterol.]
[C02DB01, dihydralazine, Formoterol may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Formoterol.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Formoterol.]
[N02AA03, hydromorphone, The metabolism of Formoterol can be decreased when combined with Hydromorphone.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Formoterol.]
[C08DB01, diltiazem, Formoterol may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dimenhydrinate.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Formoterol is combined with Dimetindene.]
[R03CC08, procaterol, Procaterol may increase the sympathomimetic activities of Formoterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Formoterol can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The risk or severity of hypokalemia can be increased when Propentofylline is combined with Formoterol.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Formoterol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Formoterol is combined with Proglumetacin.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Formoterol.]
[C05CA03, diosmin, The metabolism of Formoterol can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, The risk or severity of hypokalemia can be increased when Proxyphylline is combined with Formoterol.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Formoterol.]
[C09AA06, quinapril, Formoterol may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Formoterol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Quinupramine is combined with Formoterol.]
[A03FA02, cisapride, The metabolism of Formoterol can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Formoterol may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The metabolism of Formoterol can be decreased when combined with Remoxipride.]
[R03CC14, reproterol, Reproterol may increase the sympathomimetic activities of Formoterol.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Formoterol.]
[S02AA12, rifamycin SV, The metabolism of Formoterol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Formoterol can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The therapeutic efficacy of Formoterol can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Levocetirizine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Formoterol.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Formoterol.]
[G04BE08, tadalafil, Formoterol may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Formoterol.]
[C02KX02, ambrisentan, Formoterol may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Formoterol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Formoterol is combined with Salsalate.]
[R03AC12, salmeterol, Salmeterol may increase the sympathomimetic activities of Formoterol.]
[C01CA07, dobutamine, Dobutamine may increase the sympathomimetic activities of Formoterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Formoterol is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Formoterol can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Formoterol.]
[N06AA12, doxepin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Formoterol can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Formoterol.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Formoterol.]
[N01AB08, sevoflurane, Sevoflurane may increase the arrhythmogenic activities of Formoterol.]
[N05AD08, droperidol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the tachycardic activities of Formoterol.]
[C10AA01, simvastatin, The metabolism of Formoterol can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Formoterol may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of hypokalemia can be increased when Dyphylline is combined with Formoterol.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Formoterol.]
[C07AB13, talinolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Formoterol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Formoterol.]
[G04CA03, terazosin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Terazosin.]
[D01BA02, terbinafine, The metabolism of Formoterol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may decrease the bronchodilatory activities of Formoterol.]
[S01GA02, tetrahydrozoline, Tetryzoline may increase the sympathomimetic activities of Formoterol.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Formoterol is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Tianeptine is combined with Formoterol.]
[C09AA02, enalapril, Formoterol may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Formoterol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Toloxatone is combined with Formoterol.]
[N06BA09, atomoxetine, Atomoxetine may increase the tachycardic activities of Formoterol.]
[N03AX11, topiramate, The metabolism of Formoterol can be decreased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Formoterol is combined with Tramazoline.]
[C09AA10, trandolapril, Formoterol may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Formoterol.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Formoterol.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Triptorelin.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Tropatepine.]
[R03CC11, tulobuterol, Tulobuterol may increase the sympathomimetic activities of Formoterol.]
[N01AB04, enflurane, Enflurane may increase the arrhythmogenic activities of Formoterol.]
[C02CA06, urapidil, The therapeutic efficacy of Formoterol can be decreased when used in combination with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Formoterol.]
[L01CA04, vinorelbine, The metabolism of Formoterol can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Ephedrine may increase the sympathomimetic activities of Formoterol.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Formoterol.]
[N06AX16, venlafaxine, The metabolism of Formoterol can be decreased when combined with Venlafaxine.]
[C01CX07, xamoterol, Xamoterol may increase the sympathomimetic activities of Formoterol.]
[S01GA03, xylometazoline, Xylometazoline may increase the sympathomimetic activities of Formoterol.]
[S01EA01, epinephrine, Epinephrine may increase the sympathomimetic activities of Formoterol.]
[C09AA15, zofenopril, Formoterol may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Formoterol can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Formoterol is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Formoterol.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Formoterol.]
[C02AC02, guanfacine, Guanfacine may increase the sympathomimetic activities of Formoterol.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Formoterol.]
[G02AB03, ergonovine, Ergometrine may increase the sympathomimetic activities of Formoterol.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Formoterol.]
[N02CA02, ergotamine, Ergotamine may increase the hypertensive and vasoconstricting activities of Formoterol.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Erythromycin.]
[A02BC02, pantoprazole, The metabolism of Formoterol can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Formoterol can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Formoterol can be decreased when combined with Estradiol.]
[J04AK02, ethambutol, The metabolism of Formoterol can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Formoterol.]
[C10AA04, fluvastatin, The metabolism of Formoterol can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Formoterol is combined with Gepefrine.]
[L02AA03, ethinyl estradiol, The metabolism of Formoterol can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Formoterol.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Formoterol.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Formoterol.]
[C01CA01, etilefrine, Etilefrine may increase the sympathomimetic activities of Formoterol.]
[N01AX07, etomidate, Etomidate may increase the sympathomimetic activities of Formoterol.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Formoterol.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Formoterol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Formoterol.]
[R06AX12, terfenadine, The metabolism of Formoterol can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Formoterol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Formoterol can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Formoterol.]
[P02CA03, albendazole, The metabolism of Formoterol can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Formoterol can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Formoterol.]
[R03CC04, fenoterol, Fenoterol may increase the sympathomimetic activities of Formoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Formoterol.]
[R03CC02, albuterol, Salbutamol may increase the sympathomimetic activities of Formoterol.]
[N07AX03, cevimeline, The metabolism of Formoterol can be decreased when combined with Cevimeline.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Formoterol is combined with Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Formoterol.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Formoterol is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Formoterol can be decreased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Formoterol.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Formoterol.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Formoterol.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Formoterol.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Formoterol.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Melitracen is combined with Formoterol.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Formoterol.]
[V03AZ01, ethanol, The metabolism of Formoterol can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Formoterol can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Formoterol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Formoterol.]
[N06AB03, fluoxetine, The serum concentration of Formoterol can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Formoterol can be decreased when combined with Fluphenazine.]
[N05CD01, flurazepam, The metabolism of Formoterol can be decreased when combined with Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Formoterol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fluspirilene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Formoterol.]
[N06BX17, adrafinil, Adrafinil may increase the sympathomimetic activities of Formoterol.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol.]
[J05AE10, darunavir, The metabolism of Formoterol can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Furosemide.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Formoterol.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Formoterol is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The metabolism of Formoterol can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dasatinib.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Formoterol.]
[C01CA21, cafedrine, The risk or severity of hypokalemia can be increased when Cafedrine is combined with Formoterol.]
[J05AG04, etravirine, The metabolism of Formoterol can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Formoterol.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Formoterol.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Formoterol.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Formoterol.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the sympathomimetic activities of Formoterol.]
[C05AE01, nitroglycerin, Formoterol may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dofetilide.]
[C02CA04, doxazosin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Formoterol can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Esmolol.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Formoterol.]
[C09AA09, fosinopril, Formoterol may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Formoterol may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Formoterol can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Haloperidol.]
[N01AB01, halothane, Halothane may increase the arrhythmogenic activities of Formoterol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Quetiapine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Formoterol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Formoterol.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Formoterol.]
[R03CC05, hexoprenaline, Hexoprenaline may increase the sympathomimetic activities of Formoterol.]
[J05AG01, nevirapine, The metabolism of Formoterol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Formoterol can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Formoterol is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Oxatomide.]
[C09AA04, perindopril, Formoterol may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Formoterol may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Formoterol.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Hydroflumethiazide.]
[G04BD06, propiverine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Formoterol can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Rilmenidine may increase the sympathomimetic activities of Formoterol.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Formoterol is combined with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Formoterol.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Formoterol.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Formoterol.]
[N06AA02, imipramine, The metabolism of Formoterol can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Formoterol.]
[M03BX02, tizanidine, Tizanidine may increase the sympathomimetic activities of Formoterol.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Formoterol.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Formoterol.]
[C02CA02, indoramin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the tachycardic activities of Formoterol.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Formoterol is combined with Piperidolate.]
[N05CH02, ramelteon, The metabolism of Formoterol can be decreased when combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Formoterol.]
[G02CX01, atosiban, The risk or severity of adverse effects can be increased when Formoterol is combined with Atosiban.]
[C10AA06, cerivastatin, The metabolism of Formoterol can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may decrease the bronchodilatory activities of Formoterol.]
[C03BA02, quinethazone, Formoterol may increase the hypokalemic activities of Quinethazone.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Formoterol.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Iprindole is combined with Formoterol.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Formoterol.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Formoterol.]
[P01AX06, atovaquone, The metabolism of Formoterol can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, Isoetharine may increase the sympathomimetic activities of Formoterol.]
[C09AA16, imidapril, Formoterol may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the arrhythmogenic activities of Formoterol.]
[N04BX02, entacapone, The metabolism of Formoterol can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Formoterol can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Isoprenaline may increase the sympathomimetic activities of Formoterol.]
[C04AA01, isoxsuprine, Isoxsuprine may increase the sympathomimetic activities of Formoterol.]
[N06AX18, reboxetine, The metabolism of Formoterol can be decreased when combined with Reboxetine.]
[L04AC07, tocilizumab, The metabolism of Formoterol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Formoterol.]
[C02KD01, ketanserin, Formoterol may decrease the antihypertensive activities of Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Formoterol.]
[J02AB02, ketoconazole, The metabolism of Formoterol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Formoterol is combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Formoterol can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Formoterol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mizolastine.]
[C01CA22, arbutamine, Arbutamine may increase the sympathomimetic activities of Formoterol.]
[N04BC09, rotigotine, The metabolism of Formoterol can be decreased when combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Formoterol is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Formoterol.]
[C02AA05, deserpidine, Formoterol may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Formoterol.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Formoterol is combined with Etacrynic acid.]
[S02DA01, lidocaine, The metabolism of Formoterol can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Formoterol can be decreased when combined with Armodafinil.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Formoterol.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Lofepramine is combined with Formoterol.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Formoterol can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Formoterol.]
[L01EG01, temsirolimus, The metabolism of Formoterol can be decreased when combined with Temsirolimus.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Formoterol.]
[C02BB01, mecamylamine, Formoterol may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The metabolism of Formoterol can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Formoterol.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Formoterol.]
[N06DX01, memantine, The metabolism of Formoterol can be decreased when combined with Memantine.]
[C01CA11, mephentermine, Mephentermine may increase the sympathomimetic activities of Formoterol.]
[N03AB04, mephenytoin, The metabolism of Formoterol can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Formoterol can be decreased when combined with Methylphenobarbital.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Formoterol can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, Metaraminol may increase the sympathomimetic activities of Formoterol.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dolasetron.]
[N07BC02, methadone, The metabolism of Formoterol can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the sympathomimetic activities of Formoterol.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Methantheline is combined with Formoterol.]
[J05AF05, lamivudine, The risk or severity of adverse effects can be increased when Formoterol is combined with Lamivudine.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Formoterol.]
[H03BB02, methimazole, The metabolism of Formoterol can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, The metabolism of Formoterol can be decreased when combined with Methotrimeprazine.]
[C01CA10, methoxamine, Methoxamine may increase the sympathomimetic activities of Formoterol.]
[D05BA02, methoxsalen, The metabolism of Formoterol can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the arrhythmogenic activities of Formoterol.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Methyclothiazide.]
[C02AB01, methyldopa, Methyldopa may increase the sympathomimetic activities of Formoterol.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Methylene blue is combined with Formoterol.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Formoterol.]
[R03DA05, aminophylline, The risk or severity of hypokalemia can be increased when Aminophylline is combined with Formoterol.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Formoterol.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Formoterol.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Formoterol.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Formoterol.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Metoclopramide.]
[C03BA08, metolazone, Formoterol may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The metabolism of Formoterol can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Formoterol.]
[V04CD01, metyrapone, The metabolism of Formoterol can be decreased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Formoterol can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Formoterol is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Formoterol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Formoterol is combined with Aminophenazone.]
[C01CA17, midodrine, Midodrine may increase the sympathomimetic activities of Formoterol.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mifepristone.]
[C09CA03, valsartan, The metabolism of Formoterol can be decreased when combined with Valsartan.]
[D11AX01, minoxidil, Formoterol may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Formoterol is combined with Lisdexamfetamine.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Formoterol.]
[A04AA05, palonosetron, The metabolism of Formoterol can be decreased when combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Formoterol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Formoterol can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Pazopanib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Formoterol.]
[G04CA04, silodosin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Silodosin.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Formoterol.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Formoterol.]
[C07AA12, nadolol, Nadolol may decrease the bronchodilatory activities of Formoterol.]
[L04AC03, anakinra, The metabolism of Formoterol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may increase the sympathomimetic activities of Formoterol.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Formoterol.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Formoterol.]
[A10BG01, troglitazone, The metabolism of Formoterol can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Formoterol can be decreased when combined with Duloxetine.]
[L02BG04, letrozole, The metabolism of Formoterol can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Remifentanil is combined with Formoterol.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Levosimendan.]
[N05AX14, iloperidone, The therapeutic efficacy of Formoterol can be decreased when used in combination with Iloperidone.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the tachycardic activities of Formoterol.]
[C09CA07, telmisartan, The metabolism of Formoterol can be decreased when combined with Telmisartan.]
[C10AD02, niacin, The metabolism of Formoterol can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Formoterol.]
[C08CA04, nicardipine, The metabolism of Formoterol can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Formoterol.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Formoterol.]
[N07BA01, nicotine, The metabolism of Formoterol can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Formoterol.]
[M02AA17, niflumic acid, The metabolism of Formoterol can be decreased when combined with Niflumic acid.]
[C08CA06, nimodipine, Formoterol may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Formoterol may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Nitrendipine.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Formoterol is combined with Pramipexole.]
[C02DD01, nitroprusside, Formoterol may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the arrhythmogenic activities of Formoterol.]
[C01CA03, norepinephrine, Norepinephrine may increase the sympathomimetic activities of Formoterol.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Formoterol can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Formoterol.]
[R05DA07, noscapine, The metabolism of Formoterol can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, Nylidrin may increase the sympathomimetic activities of Formoterol.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Formoterol.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Formoterol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Formoterol can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Opipramol is combined with Formoterol.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Formoterol.]
[R03CB03, metaproterenol, Orciprenaline may increase the sympathomimetic activities of Formoterol.]
[G04CA02, tamsulosin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Formoterol can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Formoterol can be decreased when combined with Oxandrolone.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may decrease the bronchodilatory activities of Formoterol.]
[N02AA05, oxycodone, The metabolism of Formoterol can be decreased when combined with Oxycodone.]
[C01DX03, oxyfedrine, Oxyfedrine may increase the sympathomimetic activities of Formoterol.]
[S01GA04, oxymetazoline, Oxymetazoline may increase the sympathomimetic activities of Formoterol.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Formoterol.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Formoterol is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Formoterol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Formoterol.]
[N05AH05, asenapine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Formoterol is combined with Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Formoterol.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Formoterol.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Formoterol.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Formoterol.]
[C07AA23, penbutolol, Penbutolol may decrease the bronchodilatory activities of Formoterol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Formoterol can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The risk or severity of hypokalemia can be increased when Pentoxifylline is combined with Formoterol.]
[N04BC02, pergolide, Pergolide may increase the sympathomimetic activities of Formoterol.]
[C08EX02, perhexiline, The metabolism of Formoterol can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Formoterol can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Formoterol.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Formoterol.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Phenformin is combined with Formoterol.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Formoterol.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Formoterol can be decreased when combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Formoterol.]
[V03AB36, phentolamine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Formoterol can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may increase the sympathomimetic activities of Formoterol.]
[A02BC06, dexlansoprazole, The metabolism of Formoterol can be decreased when combined with Dexlansoprazole.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may increase the sympathomimetic activities of Formoterol.]
[N03AB02, phenytoin, The metabolism of Formoterol can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Formoterol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Levofloxacin.]
[C08CX01, mibefradil, The metabolism of Formoterol can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Formoterol can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Formoterol.]
[C07AA03, pindolol, Pindolol may decrease the bronchodilatory activities of Formoterol.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Formoterol.]
[P02CB01, piperazine, The metabolism of Formoterol can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Formoterol can be decreased when combined with Pipotiazine.]
[C09CA02, eprosartan, Formoterol may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Formoterol.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Formoterol.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Formoterol can be decreased when used in combination with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Formoterol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Formoterol may decrease the antihypertensive activities of Irbesartan.]
[A10BG02, rosiglitazone, The metabolism of Formoterol can be decreased when combined with Rosiglitazone.]
[A03AE01, alosetron, The metabolism of Formoterol can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Formoterol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Formoterol is combined with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Formoterol can be decreased when combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Formoterol.]
[C07AB01, practolol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Formoterol.]
[C02CA01, prazosin, The therapeutic efficacy of Formoterol can be decreased when used in combination with Prazosin.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Formoterol.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Formoterol.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Formoterol can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Formoterol can be decreased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Formoterol can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Formoterol.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Formoterol.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Formoterol.]
[C10AB05, fenofibrate, The metabolism of Formoterol can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Formoterol.]
[G03DA04, progesterone, The metabolism of Formoterol can be decreased when combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Formoterol can be decreased when combined with Propafenone.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Propantheline is combined with Formoterol.]
[N05AC01, periciazine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Formoterol can be decreased when used in combination with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Formoterol.]
[N02AC04, propoxyphene, The metabolism of Formoterol can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may decrease the bronchodilatory activities of Formoterol.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Rizatriptan is combined with Formoterol.]
[B01AC09, epoprostenol, Formoterol may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Formoterol can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Formoterol.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the sympathomimetic activities of Formoterol.]
[N05AX12, aripiprazole, The therapeutic efficacy of Formoterol can be decreased when used in combination with Aripiprazole.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Formoterol is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Formoterol is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Formoterol is combined with Methscopolamine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Formoterol can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Formoterol can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Formoterol can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Formoterol may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Formoterol.]
[J04AB02, rifampin, The metabolism of Formoterol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may increase the sympathomimetic activities of Formoterol.]
[G02CA01, ritodrine, Ritodrine may increase the sympathomimetic activities of Formoterol.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Formoterol is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Formoterol.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Formoterol.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Formoterol.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Formoterol.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Formoterol.]
[C03DA01, spironolactone, The therapeutic efficacy of Formoterol can be decreased when used in combination with Spironolactone.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Valproic acid.]
[A05AA01, chenodeoxycholic acid, The metabolism of Formoterol can be decreased when combined with Chenodeoxycholic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Formoterol.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Formoterol.]
